{
  "abstract": "Background and aim\n\nPF-07242813 (anti-CD1a) was designed to inhibit T-cell proinflammatory signaling. This analysis evaluated the safety and pharmacokinetics of single ascending doses and multiple ascending doses (MADs) of PF-07242813 in healthy participants and the pharmacodynamics of a single dose in patients with atopic dermatitis (AD).Methods\n\nIn part 1, healthy participants (aged 18-55 years) received PF-07242813 intravenously (single ascending doses), subcutaneously (MADs) or intravenously (MADs), or placebo. In part 2, patients with moderate-to-severe AD (aged 18-65 years) were randomized (2:1) to receive 1000 mg PF-07242813 intravenously or placebo. Endpoints included safety and pharmacokinetic outcomes in healthy participants and efficacy endpoints in patients with AD.Results\n\nOf the 122 participants (single ascending doses: n = 57; MADs: n = 40; AD: n = 25), 41 reported treatment-emergent adverse events (mostly mild); headache (4.9%) and alanine transaminase increase (4.9%) were the most common. Peak serum PF-07242813 concentrations occurred at 0.6-2 hours (intravenously, single ascending doses) and 73-169 hours (subcutaneously, MADs). Overall, PF-07242813 did not demonstrate clinical benefit in patients with AD.Conclusions\n\nCD1a blockade is not sufficient to produce a clinical effect in patients with AD. PF-07242813 was well tolerated and may be useful for CD1a pathway analyses. This study is registered at ClinicalTrials.gov (identifier NCT04668066).",
  "abstract_shown": true,
  "affiliations": [
    "Research and Development, Pfizer, Cambridge, Massachusetts, USA.",
    "Pfizer, Collegeville, Pennsylvania, USA.",
    "Translational Clinical Sciences, Pfizer, Cambridge, Massachusetts, USA.",
    "Inflammation and Immunology Research Unit, Pfizer, Cambridge, Massachusetts, USA."
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 10,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Spencer I Danto"
    },
    {
      "affs": [
        0
      ],
      "name": "Ruolun Qiu"
    },
    {
      "affs": [
        0
      ],
      "name": "Yifan Zhou"
    },
    {
      "affs": [
        0
      ],
      "name": "Vivek Pradhan"
    },
    {
      "affs": [
        1
      ],
      "name": "Natalie Rath"
    },
    {
      "affs": [
        2
      ],
      "name": "Karen M Page"
    },
    {
      "affs": [
        0
      ],
      "name": "Xingpeng Li"
    },
    {
      "affs": [
        0
      ],
      "name": "Elena Peeva"
    },
    {
      "affs": [
        0
      ],
      "name": "Michael S Vincent"
    },
    {
      "affs": [
        3
      ],
      "name": "Jeremy D Gale"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/29h7wmkvq1rzp.bib",
  "cited_by": 0,
  "doi": "10.1016/j.xjidi.2026.100523",
  "fulltext_url": "https://europepmc.org/articles/PMC13692157",
  "id": "29h7wmkvq1rzp",
  "issns": [
    "2667-0267"
  ],
  "landing_url": "https://europepmc.org/article/MED/42921257",
  "language": "eng",
  "licence": "CC-BY-NC-ND",
  "licence_label": "CC BY-NC-ND",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc-nd/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "openalex",
      "2708|Dermatology and Skin Diseases"
    ]
  ],
  "openalex": "W7202139428",
  "pdf_url": "https://europepmc.org/articles/PMC13692157?pdf=render",
  "pmcid": "PMC13692157",
  "pmid": "42921257",
  "published": "2026-08-10",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/29h7wmkvq1rzp.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:21:02Z",
      "native_id": "MED:42921257",
      "source": "europepmc",
      "url": "https://europepmc.org/article/MED/42921257"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2708|Dermatology and Skin Diseases",
      "subfield": "general"
    }
  ],
  "title": "A phase 1 study of PF-07242813, an anti-CD1a antibody, in healthy participants and in patients with atopic dermatitis.",
  "title_text": "A phase 1 study of PF-07242813, an anti-CD1a antibody, in healthy participants and in patients with atopic dermatitis.",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:21:02Z",
  "url": "https://research.draconitic.com/paper/29h7wmkvq1rzp",
  "venue": "JID innovations : skin science from molecules to population health",
  "versions": []
}